INS and metabolic dysfunction-associated steatotic liver disease: As shown in recent clinical trials in patients with NAFLD [5,6,7,8,9,10,11], GLP-1 agonists induce weight loss and improve insulin sensitization yet are unable to lessen or reverse fibrosis.